Equities research analysts expect that Integra Lifesciences Holdings Corp (NASDAQ:IART) will post $370.61 million in sales for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Integra Lifesciences’ earnings, with the lowest sales estimate coming in at $368.80 million and the highest estimate coming in at $373.10 million. Integra Lifesciences reported sales of $278.83 million in the same quarter last year, which indicates a positive year-over-year growth rate of 32.9%. The business is scheduled to announce its next earnings report before the market opens on Wednesday, October 31st.
On average, analysts expect that Integra Lifesciences will report full-year sales of $1.49 billion for the current financial year, with estimates ranging from $1.48 billion to $1.49 billion. For the next financial year, analysts anticipate that the company will post sales of $1.57 billion, with estimates ranging from $1.56 billion to $1.60 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Integra Lifesciences.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 25th. The life sciences company reported $0.60 EPS for the quarter, meeting the consensus estimate of $0.60. Integra Lifesciences had a net margin of 5.10% and a return on equity of 17.43%. The company had revenue of $366.20 million for the quarter, compared to analyst estimates of $368.08 million. During the same quarter last year, the business earned $0.45 earnings per share. Integra Lifesciences’s revenue was up 29.8% compared to the same quarter last year.
Several brokerages have commented on IART. Zacks Investment Research lowered shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. Oppenheimer restated a “buy” rating on shares of Integra Lifesciences in a research note on Tuesday, October 2nd. Citigroup lowered shares of Integra Lifesciences from a “buy” rating to a “neutral” rating and raised their price target for the company from $64.00 to $66.00 in a research note on Monday, July 2nd. BTIG Research restated a “buy” rating and issued a $69.00 price target on shares of Integra Lifesciences in a research note on Wednesday, September 12th. Finally, BidaskClub upgraded shares of Integra Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $62.15.
Shares of NASDAQ:IART opened at $62.14 on Tuesday. Integra Lifesciences has a 52 week low of $41.51 and a 52 week high of $67.50. The company has a market capitalization of $5.33 billion, a price-to-earnings ratio of 32.03, a PEG ratio of 1.93 and a beta of 0.57. The company has a current ratio of 3.52, a quick ratio of 2.27 and a debt-to-equity ratio of 1.10.
In other news, insider Jeffrey Mosebrook sold 1,000 shares of the stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $62.42, for a total value of $62,420.00. Following the completion of the transaction, the insider now directly owns 3,085 shares in the company, valued at $192,565.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Glenn Coleman sold 8,916 shares of the stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $63.00, for a total transaction of $561,708.00. Following the completion of the transaction, the vice president now owns 16,795 shares of the company’s stock, valued at $1,058,085. The disclosure for this sale can be found here. Insiders sold 56,592 shares of company stock valued at $3,573,584 over the last quarter. Insiders own 5.10% of the company’s stock.
Several institutional investors have recently bought and sold shares of IART. Zeke Capital Advisors LLC bought a new position in shares of Integra Lifesciences in the second quarter valued at approximately $204,000. We Are One Seven LLC bought a new position in shares of Integra Lifesciences in the third quarter valued at approximately $211,000. Eagle Boston Investment Management Inc. bought a new position in shares of Integra Lifesciences in the second quarter valued at approximately $223,000. World Asset Management Inc bought a new position in shares of Integra Lifesciences in the second quarter valued at approximately $261,000. Finally, LS Investment Advisors LLC boosted its holdings in shares of Integra Lifesciences by 99.3% in the second quarter. LS Investment Advisors LLC now owns 4,276 shares of the life sciences company’s stock valued at $275,000 after acquiring an additional 2,130 shares in the last quarter. Institutional investors and hedge funds own 84.22% of the company’s stock.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Further Reading: Dow Jones Industrial Average (DJIA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.